![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, December 29, 2013 4:50:14 PM
Great job on your analysis. I hadn't framed it that way before, that there is no control arm for OS. The independent variable for OS will be the timing of the DCVax-L treatment after SOC, not DCVax-L vs. SOC. DCVax-L is given either shortly after the initial SOC, or later after longer SOC, after the patient has crossed over.
I believe that your conclusion is correct that the crossovers can't hurt DCVax-L's odds, but could help.
But I don't think the crossovers have to have a dismal OS for the DMC to recommend unblinding. In the crossover group they will still measure the tumors. And they'll have a new baseline. The tumor size at the time of the crossover will be the starting point, not the tumor size at the start of the trial.
If the stats show that a significant percentage of the crossover patients now have shrinking tumors, even if the OS stats for the crossovers don't make a statistically significant case for unblinding, the DMC would have to see that as a strong argument for unblinding.
I raise this as a possibility because if the vaccine helps some or a lot of the crossovers, the death rate between the crossovers and the DCVax-L arm might not be statistically significant yet.
But if 30-60% of the crossovers either have shrinking or stable tumors, when prior to the crossover 100% had progressing tumors, the DMC wouldn't be able to ignore that data, regardless of the OS stats.
But it all starts with great PFS stats for DCVax-L vs. the control group. If those numbers are there, then the DMC will look at all the stats more carefully before they give NWBO their recommendation. Recommending an early halt isn't something to be taken lightly. The possibility exists that even if the DMC recommended that, that the FDA wouldn't grant early approval. Measure twice, cut once.
So if the DMC is taking their time, I think it's a positive sign. But without knowing when the events were reached and when the DMC started their analysis, it's just conjecture on my part.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM